




AdenoVerse™ Manufacturing Cell Lines for Therapeutics and Vaccines

Licensing Opportunity

- Well-characterized, genetically stable, proprietary human cell lines for biopharmaceutical production
- Licensing package includes:
 - ✓ Key intellectual property
 - ✓ Non-exclusive licensing agreement for access to GenVec's proprietary industrial technology and manufacturing cell line(s)
 - ✓ Cross-reference to FDA Master file and access to Master Cell Bank(s) as well as intellectual property associated therewith

Highlights

- Adaptable to produce a wide variety of vaccines and therapeutic vector products
- Cells are stable through multiple passages
- Bioprocess-friendly in animal protein-free suspension culture
- Exceptionally high-yield production across multiple adenovector serotypes
- Master Cell Banks
 - ✓ Thoroughly characterized with respect to safety, genetic and molecular characteristics, and stability
 - ✓ Characterization data have been submitted to the FDA in a Biological Master File



Description – ORF6 Cell Line

- Therapeutics and vaccines manufactured using this cell line have been tested in over 3,000 clinical trial subjects
- Complements for multiply-deleted adenovector production, generating Replication Competent Adenovirus (RCA)-free vector lots

Description – M2A Cell Line

- Designed to ensure the genetically stable production of vectors bearing highly toxic genes
- The USDA has accepted M2A cell products for use in vaccine production

About GenVec

GenVec is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its proprietary AdenoVerse™ gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. Current GenVec partners and collaborators include leading organizations such as Novartis and the U.S. Government.

For further information, please contact:

Sebastien Maloveste, Ph.D.
Assoc. Dir., Business Development
Tel: 240-801-8602
smaloveste@genvec.com

Adrian Riddell
Assoc. Dir., Business Development
Tel: 240-801-8600
ariddell@genvec.com

